Carrabba N, Migliorini A, Fumagalli C, et al. - Researchers assessed the long-term clinical result and prosthesis performance of the CoreValve self-expandable valve, by analyzing 182 patients consecutively managed with transcatheter aortic valve Implantation (TAVI) in a tertiary center from January 2009 to July 2017. An average follow-up of 1,026 ± 812 days revealed deaths of 111 patients. At 1 month, improvement was evident in the functional profile in all survivors, with 93.9% of them attaining NYHA class I or II. Cox analysis revealed that an independent link with all-cause death was demonstrated by the Society of Thoracic Surgeons score, left ventricular ejection fraction < 40%, and incident acute kidney injury. At 11 years, cumulative incidence of bioprosthetic valve failure (BVF) was 2.9% and that of moderate structural valve deterioration (SVD) was 9.3%. Findings of this clinical registry corroborated that favorable long-term clinical results were conferred by TAVI with the self-expandable CoreValve system, and also a reassuring low rate of significant BVF and moderate SVD was provided.